In reply
We would like to thank Drs Mataftsi and Horgan for their interest in our article and their valuable remarks. As for the specific issues raised:
Because glaucoma is a slowly progressive chronic disease, it is widely accepted that any study evaluating a real effect on glaucoma patients should be extended for at least several years. However, as we all have learned to appreciate the importance of intraocular pressure (IOP) reduction in patients with glaucoma, we strongly believe that even an interim study of IOP response during a mean follow-up of 11 months is worth reporting.